Axon guidance genes are regulated by TDP-43 and RGNEF through long-intron removal.
ALS
RGNEF
TDP‐43
hnRNPs
long‐intron processing
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
revised:
05
09
2024
received:
03
04
2024
accepted:
18
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
ppublish
Résumé
Rho guanine nucleotide exchange factor (RGNEF) is a guanine nucleotide exchange factor (GEF) mainly involved in regulating the activity of Rho-family GTPases. It is a bi-functional protein, acting both as a guanine exchange factor and as an RNA-binding protein. RGNEF is known to act as a destabilizing factor of neurofilament light chain RNA (NEFL) and it could potentially contribute to their sequestration in nuclear cytoplasmic inclusions. Most importantly, RGNEF inclusions in the spinal motor neurons of ALS patients have been shown to co-localize with inclusions of TDP-43, the major well-known RNA-binding protein aggregating in the brain and spinal cord of human patients. Therefore, it can be hypothesized that loss-of-function of both proteins following aggregation may contribute to motor neuron death/survival in ALS patients. To further characterize their relationship, we have compared the transcriptomic profiles of neuronal cells depleted of TDP-43 and RGNEF and show that these two factors predominantly act in an antagonistic manner when regulating the expression of axon guidance genes. From a mechanistic point of view, our experiments show that the effect of these genes on the processivity of long introns can explain their mode of action. Taken together, our results show that loss-of-function of factors co-aggregating with TDP-43 can potentially affect the expression of commonly regulated neuronal genes in a very significant manner, potentially acting as disease modifiers. This finding further highlights that neurodegenerative processes at the RNA level are the result of combinatorial interactions between different RNA-binding factors that can be co-aggregated in neuronal cells. A deeper understanding of these complex scenarios may lead to a better understanding of pathogenic mechanisms occurring in patients, where more than one specific protein may be aggregating in their neurons.
Identifiants
pubmed: 39360635
doi: 10.1096/fj.202400743RR
doi:
Substances chimiques
DNA-Binding Proteins
0
Guanine Nucleotide Exchange Factors
0
TARDBP protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70081Subventions
Organisme : Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA)
Organisme : Temetry Family Foundation
Informations de copyright
© 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol. 2005;64:649‐664.
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918‐1929.
Arai T, Hasegawa M, Akiyama H, et al. TDP‐43 is a component of ubiquitin‐positive tau‐negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602‐661.
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130‐133.
De Marchi F, Franjkic T, Schito P, et al. Emerging trends in the field of inflammation and proteinopathy in ALS/FTD spectrum disorder. Biomedicines. 2023;11:1599.
Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777‐794.
Moda F, Ciullini A, Dellarole IL, et al. Secondary protein aggregates in neurodegenerative diseases: almost the rule rather than the exception. Front Biosci (Landmark Ed). 2023;28:255.
Droppelmann CA, Keller BA, Campos‐Melo D, Volkening K, Strong MJ. Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. Neurobiol Aging. 2013;34:248‐262.
Keller BA, Volkening K, Droppelmann CA, Ang LC, Rademakers R, Strong MJ. Co‐aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol. 2012;124:733‐747.
Cheung K, Droppelmann CA, MacLellan A, et al. Rho guanine nucleotide exchange factor (RGNEF) is a prosurvival factor under stress conditions. Mol Cell Neurosci. 2017;82:88‐95.
Miller NL, Kleinschmidt EG, Schlaepfer DD. RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase. Curr Mol Med. 2014;14:221‐234.
Powis G, Meuillet EJ, Indarte M, Booher G, Kirkpatrick L. Pleckstrin homology [PH] domain, structure, mechanism, and contribution to human disease. Biomed Pharmacother. 2023;165:115024.
Aghazadeh B, Zhu K, Kubiseski TJ, et al. Structure and mutagenesis of the Dbl homology domain. Nat Struct Biol. 1998;5:1098‐1107.
Droppelmann CA, Campos‐Melo D, Volkening K, Strong MJ. The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. Front Cell Neurosci. 2014;8:282.
Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22‐e30.
Steinacker P, Blennow K, Halbgebauer S, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt‐Jakob disease. Sci Rep. 2016;6:38737.
Vacchiano V, Mastrangelo A, Zenesini C, et al. Plasma and CSF Neurofilament light chain in amyotrophic lateral sclerosis: a cross‐sectional and longitudinal study. Front Aging Neurosci. 2021;13:753242.
Lepine S, Castellanos‐Montiel MJ, Durcan TM. TDP‐43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis. Transl Neurodegener. 2022;11:56.
Lagier‐Tourenne C, Polymenidou M, Hutt KR, et al. Divergent roles of ALS‐linked proteins FUS/TLS and TDP‐43 intersect in processing long pre‐mRNAs. Nat Neurosci. 2012;15:1488‐1497.
Colombrita C, Zennaro E, Fallini C, et al. TDP‐43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051‐1061.
Meijering E, Jacob M, Sarria JC, Steiner P, Hirling H, Unser M. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A. 2004;58:167‐176.
Appocher C, Mohagheghi F, Cappelli S, et al. Major hnRNP proteins act as general TDP‐43 functional modifiers both in Drosophila and human neuronal cells. Nucleic Acids Res. 2017;45:8026‐8045.
Cappelli S, Spalloni A, Feiguin F, et al. NOS1AP is a novel molecular target and critical factor in TDP‐43 pathology. Brain Commun. 2022;4:fcac242.
Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position‐dependent splicing regulation by TDP‐43. Nat Neurosci. 2011;14:452‐458.
Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion‐like spreading in ALS. Nat Neurosci. 2011;14:347‐355.
Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP‐43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337‐36343.
McMillan M, Gomez N, Hsieh C, et al. RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia. Mol Cell. 2023;83:219‐236.e7.
Colombrita C, Onesto E, Megiorni F, et al. TDP‐43 and FUS RNA‐binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post‐transcriptional fate in motoneuron‐like cells. J Biol Chem. 2012;287:15635‐15647.
Sidibe H, Khalfallah Y, Xiao S, et al. TDP‐43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia. Brain. 2021;144:3461‐3476.
Ling SC. Synaptic paths to neurodegeneration: the emerging role of TDP‐43 and FUS in synaptic functions. Neural Plast. 2018;2018:8413496.
Ratti A, Buratti E. Physiological functions and pathobiology of TDP‐43 and FUS/TLS proteins. J Neurochem. 2016;138(Suppl 1):95‐111.
Conti A, Riva N, Pesca M, et al. Increased expression of myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim Biophys Acta. 2014;1842:99‐106.
Nijssen J, Aguila J, Hoogstraaten R, Kee N, Hedlund E. Axon‐Seq decodes the motor axon transcriptome and its modulation in response to ALS. Stem Cell Reports. 2018;11:1565‐1578.
Korner S, Thau‐Habermann N, Kefalakes E, Bursch F, Petri S. Expression of the axon‐guidance protein receptor Neuropilin 1 is increased in the spinal cord and decreased in muscle of a mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2019;49:1529‐1543.
Yan Y, Su J, Zhang Z. The CXCL12/CXCR4/ACKR3 response axis in chronic neurodegenerative disorders of the central nervous system: therapeutic target and biomarker. Cell Mol Neurobiol. 2022;42:2147‐2156.
Luo Y, Xue H, Pardo AC, Mattson MP, Rao MS, Maragakis NJ. Impaired SDF1/CXCR4 signaling in glial progenitors derived from SOD1(G93A) mice. J Neurosci Res. 2007;85:2422‐2432.
Andres‐Benito P, Povedano M, Dominguez R, et al. Increased C‐X‐C motif chemokine ligand 12 levels in cerebrospinal fluid as a candidate biomarker in sporadic amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21:8680.
Rabinovich‐Nikitin I, Ezra A, Barbiro B, Rabinovich‐Toidman P, Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS. J Neuroinflammation. 2016;13:123.
Janssens R, Struyf S, Proost P. Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev. 2018;44:51‐68.
Bowerman M, Murray LM, Boyer JG, Anderson CL, Kothary R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 2012;10:24.
Li M, Yasumura D, Ma AA, et al. Intravitreal administration of HA‐1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. PLoS One. 2013;8:e56026.
Zhao YF, Zhang Q, Xi JY, Li YH, Ma CG, Xiao BG. Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP‐mouse model of Parkinson's disease. J Neurol Sci. 2015;353:28‐37.
Gunther R, Balck A, Koch JC, et al. Rho kinase inhibition with Fasudil in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis‐symptomatic treatment potential after disease onset. Front Pharmacol. 2017;8:17.
Takata M, Tanaka H, Kimura M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170:341‐351.
Roser AE, Tonges L, Lingor P. Modulation of microglial activity by rho‐kinase (ROCK) inhibition as therapeutic strategy in Parkinson's disease and amyotrophic lateral sclerosis. Front Aging Neurosci. 2017;9:94.
Pellecchia S, De Martino M, Esposito F, Quintavalle C, Fusco A, Pallante P. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells. Cell Cycle. 2021;20:716‐729.
Schwartz F, Neve R, Eisenman R, Gessler M, Bruns G. A WAGR region gene between PAX‐6 and FSHB expressed in fetal brain. Hum Genet. 1994;94:658‐664.
Tyagi R, Shenoy AR, Visweswariah SS. Characterization of an evolutionarily conserved metallophosphoesterase that is expressed in the fetal brain and associated with the WAGR syndrome. J Biol Chem. 2009;284:5217‐5228.
Schumann A, Bar KJ. Autonomic aging—a dataset to quantify changes of cardiovascular autonomic function during healthy aging. Sci Data. 2022;9:95.
Maingret V, Barthet G, Deforges S, Jiang N, Mulle C, Amedee T. PGE(2)‐EP3 signaling pathway impairs hippocampal presynaptic long‐term plasticity in a mouse model of Alzheimer's disease. Neurobiol Aging. 2017;50:13‐24.
Georgomanolis T, Sofiadis K, Papantonis A. Cutting a long intron short: recursive splicing and its implications. Front Physiol. 2016;7:598.
Burnette JM, Miyamoto‐Sato E, Schaub MA, Conklin J, Lopez AJ. Subdivision of large introns in Drosophila by recursive splicing at nonexonic elements. Genetics. 2005;170:661‐674.
Duff MO, Olson S, Wei X, et al. Genome‐wide identification of zero nucleotide recursive splicing in Drosophila. Nature. 2015;521:376‐379.
Grellscheid SN, Smith CW. An apparent pseudo‐exon acts both as an alternative exon that leads to nonsense‐mediated decay and as a zero‐length exon. Mol Cell Biol. 2006;26:2237‐2246.
Sibley CR, Emmett W, Blazquez L, et al. Recursive splicing in long vertebrate genes. Nature. 2015;521:371‐375.
Wan Y, Anastasakis DG, Rodriguez J, et al. Dynamic imaging of nascent RNA reveals general principles of transcription dynamics and stochastic splice site selection. Cell. 2021;184:2878‐2895.e20.
Susnjar U, Skrabar N, Brown AL, et al. Cell environment shapes TDP‐43 function with implications in neuronal and muscle disease. Commun Biol. 2022;5:314.
Bampton A, Gatt A, Humphrey J, et al. HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol. 2021;142:609‐627.
Gittings LM, Foti SC, Benson BC, Gami‐Patel P, Isaacs AM, Lashley T. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD‐FUS. Acta Neuropathol Commun. 2019;7:18.
Davidson YS, Robinson AC, Flood L, et al. Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP‐43‐immunoreactive neurites in semantic dementia but not with other TDP‐43 pathological subtypes of frontotemporal lobar degeneration. Acta Neuropathol Commun. 2017;5:54.